Stock Track | Twist Bioscience Plummets 5.10% Pre-Market After Barclays Cuts Target Price

Stock Track11-17

Shares of Twist Bioscience Corp (TWST) plummeted 5.10% in pre-market trading on Monday, following a target price cut by Barclays. The sharp decline comes as investors react to the lowered expectations from a major financial institution.

Barclays, in a note released early Monday, reduced its target price for Twist Bioscience from $40 to $37. This adjustment represents a 7.5% decrease in the bank's valuation of the company. The reasons behind Barclays' decision were not immediately clear, but such moves are typically based on reassessments of a company's growth prospects, financial health, or industry conditions.

The market's swift and significant reaction to this target price cut underscores the weight that analyst opinions carry, especially those from prominent financial institutions like Barclays. Investors often use these price targets as benchmarks for their own investment decisions. As trading continues throughout the day, it remains to be seen whether Twist Bioscience can recover from this early morning setback or if the downward pressure will persist.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment